Alnylam Pharmaceuticals Inc (ALNY)vsVertex Pharmaceuticals Inc (VRTX)
ALNY
Alnylam Pharmaceuticals Inc
$296.11
-4.32%
HEALTHCARE · Cap: $39.51B
VRTX
Vertex Pharmaceuticals Inc
$423.92
+1.40%
HEALTHCARE · Cap: $108.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 180% more annual revenue ($12.00B vs $4.29B). VRTX leads profitability with a 32.9% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.59. VRTX earns a higher WallStSmart Score of 66/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$2429.90
Current Price
$296.11
$2133.79 discount
Margin of Safety
+56.4%
Fair Value
$973.13
Current Price
$423.92
$549.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 49.7x book value
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.6x leaves little room for execution misses.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.37 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 65/100), backed by strong 32.9% margins. ALNY offers better value entry with a 86.7% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?